MS
ALNY icon

Maven Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Maven Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,086
Closed -$862K – 959
2021
Q4 		$862K Buy
+5,086
New +$945K 0.02% 395

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maven Securities's ALNY Position: Q1 2022 in Review

Maven Securities sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 5,086 shares — an estimated $862K sold.

Maven Securities first reported a position in ALNY in Q4 2021 and held it in 1 quarter. The position peaked at $862K in Q4 2021. 443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Maven Securities reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 5,086 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $862K.
  • Maven Securities first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Maven Securities's Alnylam Pharmaceuticals position peaked at $862K in Q4 2021.
  • 443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.